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ABSTRACT
Objective To compare the distance between the sphenoid
and frontal bones on three-dimensional (3D) ultrasound
in euploid and trisomy-21 fetuses at 16–24 weeks’
gestation.
Methods We acquired 3D volumes of the fetal profile
from 80 normal and 30 trisomy-21 fetuses at 16–24
weeks’ gestation. We used the multiplanar mode to obtain
the mid-sagittal plane and measured the sphenofrontal
distance as the shortest distance between the most anterior
edge of the sphenoid bone and the lowest edge of the
frontal bone.
Results In normal fetuses, the sphenofrontal distance
increased linearly with gestational age, from 15.1 mm
at 16 weeks to 18.2 mm at 24 weeks. In fetuses
with trisomy 21, the mean sphenofrontal distance delta
value was significantly smaller than in normal cases
(–3.447 mm (95% CI, –5.684 to –1.211 mm); P<0.01).
The sphenofrontal distance was below the 5th and 1st
percentiles of the normal range in 29 (96.7%) and 27
(90.0%) trisomy-21 fetuses, respectively.
Conclusions The sphenofrontal distance is shorter at
16–24 weeks’ gestation in fetuses with trisomy 21 than in
normal fetuses. A reduction in the growth of the anterior
cranial base contributes to the mid-facial hypoplasia
observed in fetuses with trisomy 21. Copyright © 2016
ISUOG. Published by John Wiley & Sons Ltd.
INTRODUCTION
Ultrasound examination of the fetal profile in the second
and third trimesters of pregnancy enables the assessment
of several facial measurements that are significantly
different in fetuses with trisomy 21 from in those that
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are chromosomally normal. Previous studies have shown
that trisomy-21 fetuses have an increased prevalence of
nasal bone absence or hypoplasia1, prenasal thickening2,
wide frontomaxillary facial angle3, increased prenasal
thickness (PT):nasal bone (NB) length ratio4 and high
prefrontal space ratio (PFSR)5.
Postnatal radiological studies have shown that indi-
viduals with trisomy 21 also have growth reduction in
the sagittal portion of the endocranium, mid-facial area,
cranial base and frontal bone6–9. These changes lead
to vertical hypoplasia of the central structures of the
cranium, lowering the position of the sella turcica and flat-
tening the cranial base. It has been reported that children
and infants with trisomy 21 have a significantly shorter
anterior cranial base length than do normal controls8,9.
The aim of this study was to compare the dis-
tance between the sphenoid and frontal bone on
three-dimensional (3D) ultrasound, as a measure of the
anterior cranial base length, in fetuses with trisomy 21
and in normal fetuses at 16–24 weeks’ gestation.
METHODS
We examined the fetal profile using stored 3D ultrasound
volumes of the fetal head that had been acquired from
pregnant women undergoing an ultrasound examination
for any indication at our fetal medicine units between 16
and 24 weeks’ gestation. One operator selected the 3D
volumes from two groups of patients. The first group
comprised 80 appropriately growing fetuses with no
sonographic evidence of fetal abnormality. The second
group comprised 30 fetuses with trisomy 21, confirmed
by chorionic villus sampling or amniocentesis that was
carried out because of a high risk for aneuploidy. In
19 (63.3%) cases maternal age was 35 years or more
and in 21 (70.0%) cases there was at least one fetal
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Figure 1 Ultrasound images of facial profile of a euploid fetus (a) and a fetus with trisomy 21 (b) at 20 weeks’ gestation, showing
measurement of sphenofrontal distance ( ).
abnormality or sonographic marker of chromosomal
defect, including cardiac defects (n = 7), duodenal atresia
(n = 1), facial cleft (n = 1), mild ventriculomegaly (n = 4),
nuchal edema (n = 10), intracardiac echogenic focus
(n = 3) and hyperechogenic bowel (n = 4).
Each 3D ultrasound volume of the fetal head was
acquired transabdominally in the mid-sagittal plane using
a RAB 4–8-MHz probe (Voulson 730 and E8 Expert, GE
Medical Systems, Zipf, Austria), ensuring that the angle
between the transducer and the long axis of the fetal
nose was close to 45◦. The 3D volumes were examined
offline by an operator who was not aware of the clinical
information or fetal karyotype, using the multiplanar
mode to confirm the exact mid-sagittal plane and to
make minor corrections from the original acquisition
plane when necessary. The exact mid-sagittal plane was
defined by the presence of the nose, upper and lower
lips, the maxilla (primary palate) and chin anteriorly,
and by the presence of the secondary palate with
the overlying vomeral bone posteriorly10. The anterior
portion of the sphenoid bone was visualized on the image
as an echogenic bony structure positioned dorsally and
superiorly with respect to the posterior edge of the vomeral
bone. The sphenofrontal distance was measured from the
most anterior edge of the sphenoid bone to the lowest edge
of the frontal bone using on-screen calipers (Figure 1).
In 50 randomly selected cases the sphenofrontal
distance was measured independently by two operators
to assess interobserver agreement, and in 60 randomly
selected cases the distance was measured on two occasions
by the same operator to assess intraobserver agreement.
Statistical analysis
Regression analysis was used to determine the significance
of the association between sphenofrontal distance and
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Figure 2 Sphenofrontal distance against gestational age in 80
euploid ( ) and 30 trisomy-21 ( ) fetuses, plotted on 5th, 50th and
95th ( ) and 1st and 99th ( ) percentiles of normal range.
gestational age (GA). The Kolmogorov–Smirnov test
was used to confirm the normality of the measurements
in chromosomally normal and trisomy-21 fetuses. The
values of sphenofrontal distance were then expressed
as a difference from the appropriate expected mean for
GA (delta value). Independent samples t-test was used
to compare mean sphenofrontal distance delta values
between normal and trisomy-21 fetuses. Bland–Altman
analysis was used to compare the measurement agree-
ment and bias for a single observer and between two
observers11.
The data were analyzed using the statistical package
SPSS 19.0 (IBM Corp., Armonk, NY, USA) and Excel for
Windows 2010 (Microsoft Corp., Redmond, WA, USA),
and P< 0.05 was considered statistically significant.
Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2016; 48: 177–180.
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Figure 3 Mean difference and 95% limits of agreement between paired measurements of sphenofrontal distance at 16–24 weeks’ gestation
in fetuses with trisomy 21 and normal fetuses, obtained by same observer (a) and by two different observers (b).
RESULTS
In the 80 normal fetuses, median maternal age was 32
(range, 16–44) years and median GA at examination
was 20 (range, 16–24) weeks. The median sphenofrontal
distance increased linearly with GA, from 15.1 mm
at 16 weeks to 18.2 mm at 24 weeks (sphenofrontal
distance = 10.079 + (0.342 × GA); r = 0.654; P< 0.01;
SD, 0.886).
In the 30 fetuses with trisomy 21, median maternal
age was 36 (range, 20–44) years and median GA at
examination was 20 (range, 16–24) weeks. In this group,
mean sphenofrontal distance delta value was significantly
smaller than that of normal fetuses (–3.447 mm (95% CI,
–5.684 to –1.211 mm); P< 0.01). The sphenofrontal
distance was below the 5th and 1st percentiles of the
normal range in 29 (96.7%) and 27 (90.0%) fetuses,
respectively (Figure 2).
The mean difference and 95% limits of agreement
(LOA) between paired measurements of sphenofrontal
distance made by the same observer were 0.113 mm
(95% LOA, –0.674 to 0.901 mm) and the mean
difference between paired measurements made by two
different observers was 0.178 mm (95% LOA, –0.856 to
1.212 mm) (Figure 3).
DISCUSSION
The findings of this study provide evidence that the
sphenofrontal distance is reduced at 16–24 weeks’
gestation in fetuses with trisomy 21 compared with
normal cases. Our results are consistent with those
of previous postnatal studies examining cephalometric
parameters in individuals with trisomy 21. Alio et al.8
measured the distance between the mid-point of the sella
turcica and the nasion (S–N) on postnatal radiograms
S N
Figure 4 Postnatal radiogram of skull of a normal child, showing
measurement of anterior cranial base as distance ( ) between
mid-point of sella turcica (S) and nasion (N).
(Figure 4) and they reported that this was significantly
shorter in 47 subjects with trisomy 21 aged between 8
and 18 years than in 38 normal cases. Similarly, Suri et al.9
examined the S–N distance in 25 children with trisomy
21 and showed that the measurements were significantly
smaller than in normal controls.
In this study, the landmarks used to measure the
anterior cranial base length were different from those
used in radiological studies. First, only a portion of the
sphenoid bone can usually be visualized on obstetric
ultrasound in the scanning plane required to obtain
the fetal profile owing to shadowing from the anterior
craniofacial bony structures. Therefore, for measurement
of the sphenofrontal distance we selected the most anterior
Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2016; 48: 177–180.
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border of the bone, which can be seen in most cases.
Second, we used the lower edge of the frontal bone rather
than the nasion because the frontal bone is more readily
identified on fetal ultrasound, and this was reflected by
good reproducibility of the measurements, which were
within 1.2 mm in 95% of the cases assessed by two
independent operators.
Previous sonographic studies have demonstrated that
second- and third-trimester fetuses with trisomy 21 show
signs of mid-facial hypoplasia, which can be assessed
by measuring NB length1, PT2 and PFSR5. Our results
suggest that a contribution to the flat face of fetuses with
trisomy 21 is also provided by a shorter sphenofrontal
distance, which could be due to dorsal displacement of
the lower portion of the frontal bone (Figure 1).
A recent retrospective study compared the measure-
ments of several ultrasound markers between a large num-
ber of fetuses with trisomy 21 and normal cases, showing
that the most significant differences were observed for
PT:NB ratio and PFSR12. At a false-positive rate of
5%, PT:NB ratio and PFSR were abnormal in about
86% and 80% of trisomy-21 fetuses, respectively. Our
results are not suitable for determining the performance
of sonographic measurement of sphenofrontal distance
in second-trimester screening for trisomy 21 because the
measurements were undertaken on stored 3D volumes
from two selected groups of patients. Therefore, larger
studies would be required to define the clinical value of
measuring the sphenofrontal distance in routine practice
and to assess the feasibility and reproducibility of the
measurements using two-dimensional ultrasound.
In the last 15 years, screening for trisomy 21 has
seen a major shift in timing of screening towards the
first trimester of pregnancy owing to the widespread
introduction of combined testing at 11–13 weeks’
gestation, which can detect about 90% of cases with
trisomy 21 for a false-positive rate of about 5%13. More
recently, it has been shown that cell-free DNA (cfDNA)
testing of maternal blood from as early as 10 weeks’
gestation can detect more than 99% of fetuses with
trisomy 21, for a false-positive rate of about 0.1%14.
Therefore, the prevalence of trisomy 21 in the second
trimester of pregnancy in women who had prior screening
by combined and/or cfDNA testing is very low, and
the routine use of sonographic soft-markers in these
cases may produce a significant increase in the rate of
invasive testing, especially if the 95th or 5th percentile of
a given measurement is taken as the cut-off. However,
second-trimester pregnancies that have not undergone
prior testing can benefit from assessment of sonographic
markers to calculate a patient-specific risk for trisomy 21,
which can be obtained by multiplying the background
maternal age-related risk by the positive or negative
likelihood ratio for each of the examined markers15.
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